Avascular Necrosis (Osteonecrosis) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Avascular necrosis (AVN) of the femoral head is caused by the interruption of blood supply to the bone of the proximal femur. The loss of blood supply can result from both traumatic and non-traumatic causes and leads to cell death (osteonecrosis). Significant necrosis leads to the total collapse of the overlying articular cartilage of the femoral head secondary to the underlying necrotic subchondral bone failure. This occurs before revascularization and regeneration of the necrotic bone can occur due to loss of the underlying structural rigidity of the affected bone as osteoclasts resorb it. The end result of this process is early osteoarthritis (OA) of the hip. The patient will often require a total hip replacement as the osteoarthritis progresses. AVN occurs in 15% to 50% of cases of femoral neck and head fractures and 10% to 25% of hip dislocations. Internal fixation is generally preferred in young patients to save the natural femoral head after a fracture. In contrast, in older patients and elderly patients, primary arthroplasty may be performed to restore mobility.
Total diagnosed avascular necrosis (AVN)
cases range from 25,500 to 31,750 cases yearly in the USA.
The competitive
landscape of Avascular Necrosis (Osteonecrosis) includes country-specific
approved and pipeline therapies. Any asset/product-specific designation,
review, and Accelerated Approval are tracked and supplemented with analyst
commentary.
KOLs insights of Avascular Necrosis
(Osteonecrosis) across 8 MM market from the center of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Avascular
Necrosis (Osteonecrosis) Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 OSSGROW® Regrow
Biosciences Phase 2
2 Ixmyelocel-T Vericel
Corporation Phase 3
3 Core decompression/PREOB® implantation Bone Therapeutics S.A Phase 2
Comments
Post a Comment